Bacterial coinfection among coronavirus disease 2019 patient groups: an updated systematic review and meta-analysis

S. Soltani[1,2], S. Faramarzi[3], M. Zandi[1,2], R. Shahbahrami[2], A. Jafarpour[2,4], S. Akhavan Rezayat[5], I. Pakzad[6], F. Abdi[7], P. Malekifar[8] and R. Pakzad[9,10]

1) Department of Virology, School of Public Health, 2) Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, 3) Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, 4) Gerash Amir-al-Momenin Medical and Educational Center, Gerash University of Medical Sciences, Gerash, 5) Department of Management & Health Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, 6) Medical Microbiology, Department of Microbiology, School of Medicine, Ilam University Medical Sciences, Ilam, 7) School of Nursing and Midwifery, Alborz University of Medical Sciences, Karaj, 8) Epidemiology, Department of Epidemiology, School of Public Health, Tehran University Medical Sciences, Tehran, 9) Epidemiology, Department of Epidemiology, Faculty of Health and 10) Student Research Committee, Ilam University Medical Sciences, Ilam, Iran

Abstract

The pandemic of severe acute respiratory syndrome coronavirus 2 raised the attention towards bacterial coinfection and its role in coronavirus disease 2019 (COVID-19) disease. This study aims to systematically review and identify the pooled prevalence of bacterial coinfection in the related articles. A comprehensive search was conducted in international databases, including MEDLINE, Scopus, Web of Science, and Embase, to identify the articles on the prevalence of bacterial coinfections in COIVD-19 patients from 1 December 2019 until 30 December 2020. All observational epidemiological studies that evaluated the prevalence of bacterial coinfections in patients with COVID-19 were included without any restriction. Forty-two studies including a total sample size of 54,695 were included in the analysis. The pooled estimate for the prevalence of bacterial coinfections was 20.97% (95% CI: 15.95–26.46), and the pooled prevalence of bacterial coinfections was 5.20% (95% CI: 2.39–8.91) for respiratory subtype and 4.79% (95% CI: 0.11–14.61) for the gastrointestinal subtype. The pooled prevalence for Eastern Mediterranean Regional Office and South-East Asia Regional Office was 100% (95% CI: 82.35–100.00) and 2.61% (95% CI: 1.74–3.62). This rate of coinfection poses a great danger towards patients, especially those in critical condition. Although there are multiple complications and adverse effects related to extensive use of antibiotics to treat patients with COVID-19, it seems there is no other option except applying them, and it needs to be done carefully.
© 2021 The Authors. Published by Elsevier Ltd.

Corresponding authors: P. Malekifar, Department of Epidemiology, School of Public Health, Tehran University of Medical Sciences, Poursina Street, PO Box: 6446-14155, Tehran, Iran
R. Pakzad, Department of Epidemiology, Faculty of Health, Ilam University Medical Sciences, Banganjab, Ilam, Iran
E-mails: poonehmalekifar@gmail.com (P. Malekifar), reza-pakzad2010@yahoo.com (R. Pakzad)

These authors are co-first authors.

Introduction

Bacterial coinfection played an important role in escalating the morbidity and mortality rate during previous viral outbreaks and pandemics [1]. Most patient's death during 1918–1919 influenza pandemic was related to bacterial co-pathogens rather than the virus itself [2]. During H1N1 pandemics, several studies recorded the high prevalence of secondary and bacterial

coinfection [3]. It was also reported that people with bacterial coinfection showed high number of mortalities. Critically ill patients showed greater percentage of coinfection compared with hospitalized patients [4]. Previous experience during other respiratory viral infections supported the use of antibiotics; so, at the onset of COVID-19 infection, early guidelines for COVID-19 treatment suggested the use of antibiotics in all the patients [5,6]. Identification of prevalence of bacterial coinfection is crucial for the initial empiric antibiotic treatment, in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients. The different possible complications could occur because of the extensive implication of antibiotics in patients. Antibacterial resistance is one of the challenges because of this amount of antibiotics use, which can affect the societies in the next years [7,8]. But because of similar clinical and radiological manifestation of some respiratory bacterial pathogen, such as *pneumococcal, staphylococcal*, and *Klebsiella* with COVID-19, it is difficult to decide which patients should receive antibiotics treatment, especially at the first encounter with the patients [9].

Materials and methods

All steps in this systematic review and meta-analysis study were based on preferred reporting items for systematic review and meta-analysis guidelines [10] and registered in the International Prospective Register of Systemic Reviews with CRD42021240030. Using related keywords such as "COVID-19", "Coronavirus", "SARS-CoV-2 infection", "SARS-CoV-2", "Polymicrobial Infection", "Bacterial AND Coinfections", "Bacterial AND Secondary Infections", and "Mixed Infections", all related articles were retrieved.

Method of literature search
A complete and comprehensive search without any language restrictions was conducted in international databases, including MEDLINE, Scopus, Web of Science, and Embase, to identify the articles on the prevalence of bacterial coinfections in patients with COIVD-19 from 1 December 2019 until 30 December 2020, in English and non-English language. Other sites, including Medrxiv and Social Science Research Network (SSRN), were also searched to identify the unofficially published researches. The text words and Medical Subject Headings (MeSH) terms of COIVD-19 and coinfections were used to search. The PICOTS in our study was as follows:

Population: Patients with COVID-19
Intervention: None
Comparison: None
Outcome: Prevalence of bacterial coinfections
Time: from 1 December 2019 until 30 December 2020
Study design: Observational study

The search strategy is described below that is applied based on PICOTS for MEDLINE (MeSH) and then used in other databases:

1. COVID-19 [text word] OR COVID-19 [Mesh term]
2. Coronavirus Disease-19 [text word] OR Coronavirus Disease-19 [Mesh term]
3. SARS-CoV-2 infection [text word] OR SARS-CoV-2 infection [Mesh term]
4. 1 OR 2 OR 3
5. Prevalence [text word] OR Prevalence [Mesh term]
6. Frequency [text word] OR Frequency [Mesh term]
7. Incidence [text word] OR Incidence [Mesh term]
8. 5 OR 6 OR 7
9. Coinfection [text word] OR Coinfection [Mesh term]
10. Mixed Infection [text word] OR Mixed Infection [Mesh term]
11. Polymicrobial Infection [text word] OR Polymicrobial Infection [Mesh term]
12. Bacterial Coinfection [text word] OR Bacterial Coinfection [Mesh term]
13. 9 OR 10 OR 11 OR 12
14. 4 AND 8 AND 13

Google Scholar was used to accessing grey literature. Also, a bacteriology expert was consulted to find relevant articles, and also, we try to find other articles by handsearching from the references list of relevant articles. Then, all data were imported to Endnote X6, and after removing the duplicated articles, the remaining studies has been screening in three steps. In the first step, the titles were reviewed, and if the article was relevant, then the abstract and then the full text of the articles were reviewed. The three steps were followed independently by two raters, "Reza Pakzad" and "Saber Soltani", and interrater discrepancies were resolved based on the third person's opinion, "Iraj Pakzad". Blinding and task separation were applied in study procedure selection. The interrater agreement was 89%.

Inclusion and exclusion criteria
All observational epidemiological studies, including cohort, cross-sectional, and case series studies around the world, that examined the prevalence of bacterial coinfections in patients with COVID-19 were included without any restriction. Case reports and case series with less than ten sample sizes were excluded. Also, editorials, commentaries, case−control, randomized clinical trial, and reviews were excluded.

Data extraction

In addition to general information, including the name of authors, year, country, study design, sample size or number of patients with COVID-19, age, sex, and other data including number and type of bacterial coinfections were extracted in all studies. Herein, patients with COVID-19 (confirmed cases based on molecular tests such as PCR) with even a single bacterial coinfection were considered in the study.

Variable definition

Bacteria types were classified based on transmission way and clinical signs. Countries were categorized based on the latest WHO definition that includes the following six regions: Regional Office for Africa, Regional Office of Americas (AMRO), Regional Office for the Eastern Mediterranean, Regional Office for Europe, Regional Office for South-East Asia (SEARO), and the Regional Office for the Western Pacific (WPRO).

Quality assessment

The Newcastle-Ottawa Scale for case reports/case series and observational study was used to assess the quality of the included studies [11]. This scale has three sections: 1, selection (4 items, maximum score: 4 points); 2, confounder (1 item, maximum score: 1 point); and 3, exposure (2 items, maximum score: 2 points). The studies were evaluated by two raters (Reza Pakzad and Saber Soltani) independently, and a total score was calculated for each study. The studies were then assigned to one of the following categories accordingly: very good studies: 6−7 scores; good studies: 4−5 scores; satisfactory studies: 2−3 scores; unsatisfactory studies: 0−1 score [12].

Statistical analysis

All analysis was conducted with Stata software 14.0 (College Station, TX). As previous studies [13−16], the number of COVID-19 cases, the prevalence of bacterial coinfections in COVID-19, and its different bacterial types were extracted. Heterogeneity was determined using Cochran's Q test of heterogeneity, and the I^2 index was used to quantify heterogeneity. Following the Higgins classification approach, I^2 values above 0.7 were considered as high heterogeneity. The pooled prevalence with 95% CI was calculated using the "metaprop" command, and to estimate the pooled prevalence, we used the random effects model. It should be noted the "Freeman-Tukey double-arcsine transformation" method is used for estimating 95% CI to keep the value between 0% and 100%. The meta-regression analysis was used to examine age, WHO region, and sample size as factors affecting heterogeneity among studies. The "metabias" command was used to check the publication bias. If there was any publication bias, the prevalence rate was adjusted with the "meta-trim" command using the trim-and-fill method. In all analyses, a significance level of 0.05 was considered.

Results

Overall, 8700 studies were found through databases, and 138 studies were identified through other sources (SSRN: 4, Medrxiv: 8, grey literature: 8, bacteriology expert: 3, and handsearching: 115). After excluding redundant articles, 7260 studies remained. Screening was done in three steps. In the first step, 5136 studies were excluded after reviewing the titles, and 2124 articles remained. After reading abstracts, 1732 studies were excluded from the list. Then, the full text of the remaining 392 studies was reviewed, and 350 studies were excluded. Finally, 42 studies [17−58] with a total sample size of 54,695 were included in the analysis. The flowchart of this selection process is shown in Fig. 1, and the characteristic of the studies was showed in Table 1 and Supplement 1. European region had the highest number of studies (15 studies), and Eastern Mediterranean Region and Western Pacific had the lowest number of studies. All studies were published during the year 2020. The minimum and maximum age range of the subjects was for a study by Wu *et al.* (mean age = 6 years) and a study by D'Onofrio *et al.* (mean age = 73 years), respectively. The study setting assessment indicates 25 (59.53%) of the studies are cohort (prospective and retrospective), 12 (28.57%) are case series (prospective and retrospective), and 5 (11.9%) are cross-sectional.

Pooled prevalence of bacterial coinfections in patients with COVID-19

The prevalence of bacterial coinfections in all included studies was listed in Table 1. Also, Fig. 2 showed the forest plot for the prevalence of bacterial coinfections. The minimum and maximum reported prevalence of bacterial coinfections were reported by Hazra *et al.* (prevalence: 0%; 95% CI: 0−0.80) in Chicago [27] and by Sharifipour *et al.* (prevalence: 100%; 95% CI: 82.35−100) in Iran [47]. Based on Fig. 2 using random effects model approach, the pooled estimate for the prevalence of bacterial coinfections was 20.97% (95% CI: 15.95−26.46). This means that in overall, of every 100 people with COVID-19, 16−26 people have bacterial coinfections.

Pooled prevalence of bacterial coinfections based on different subgroups

Fig. 3 shows the pool prevalence of bacterial coinfections based on bacteria subtype, different place, and study type. The pooled prevalence of bacterial coinfections was (5.20; 95% CI:

FIG. 1. PRISMA flow diagram of the process of study selection for analysis.

2.39−8.91) for respiratory subtype and (4.79%; 95% CI: 0.11−14.61) for gastrointestinal subtype. The most and least pooled prevalence of bacterial coinfections based on study design was estimated in case series studies with 42.82% (95% CI: 18.42−69.19) and in cross-sectional studies with 1.82% (95% CI: 0.0−8.88), respectively. The pooled prevalence for WPRO and AMRO was 20.15% (95% CI: 8.54−34.96) and 13.97% (95% CI: 2.58−32.09), respectively. More detail was shown in Fig. 3.

Heterogeneity and meta-regression
Table 2 presents the results of the heterogeneity. According to Cochran's Q test of heterogeneity, there was significant heterogeneity among studies ($p < 0.001$). The I^2 index for total bacterial coinfections was 99%. According to meta-regression results, the age (coefficient: −0.205; $p = 0.643$), sample size (coefficient: −0.001; $p = 0.215$), and WHO region size (coefficient: −5.304; $p = 0.262$) had no significant effect on heterogeneity among studies (Fig. 4A and B). Type of the study (coefficient: 20.274; $p = 0.007$) had significant effect on heterogeneity among studies.

Publication bias
Based on the results of Begg's test, a significant publication bias was observed for total bacterial coinfections (Z score: 4.11; $p < 0.001$). Therefore, the trim-and-fill−adjusted pooled prevalence of bacterial coinfections (23.55%; 95% CI: 18.38−28.73)

was generated, which was not significantly different from the original pooled prevalence (20.97%; 95% CI: 15.95−26.46), and the mean results have robustness.

Discussion

Critically ill patients are more prone to bacterial coinfection compared with other infected individuals. Critically ill patients demonstrated 8.1% of coinfection, which is slightly more compared with 5.9% in hospitalized individuals [59]. Another meta-analysis article showed that 7% of patients were infected with bacterial pathogens [60]. Bacterial coinfection in the meta-analysis study was observed in 3.5% of patients. Bacterial secondary infection was identified in 14.3% of patients. This meta-analysis indicated that the most common bacterial coinfection amongst patients with COVID-19 were *Mycoplasma pneumonia*, *Pseudomonas aeruginosa*, and *Haemophilus influenzae*. This study also mentioned 3% of the patients were coinfected with viruses. The median age ranges from 42 to 63 years in most of the studies included in this meta-analysis [60].

The overall prevalence of bacterial coinfection in patients with COVID-19 was 6.9%. Nearly all the studies indicated that the patients received some kind of antibiotics [59]. Bacterial coinfection plays an undeniable role in increasing morbidity and mortality rate in viral pandemics, such as influenza [61].

TABLE 1. Characteristics of the included studies in present systematic review and meta-analysis

Author	Country	Study Design	Publication year	Mean or Age	Sample Size	Bacterial Coinfections Prevalence, % (95% CI)
Zhu et al. [58]	China	Retrospective case series	2020	51	257	91.83 (87.78–94.87)
Blasco et al. [17]	Spain	Retrospective case series	2020	64	183	0.55 (0.10–3.10)
Contou et al. [20]	France	Retrospective case series	2020	61	92	95.65 (89.24–98.80)
Sarinoglu et al. [45]	Turkey	Cross-sectional	2020	NA	30	6.67 (0.82–22.7)
Chauhdary et al. [18]	Brunei	Case series	2020	NA	141	3.55 (1.16–8.8)
Cheng et al. [19]	China	Retrospective cohort	2020	36	62	40.32 (28.50–53.55)
D'Onofrio et al. [21]	Belgium	Cohort	2020	73	110	2.73 (0.57–7.76)
Fu et al. [22]	China	Retrospective cohort	2020	NA	101	4.95 (1.63–11.18)
Garcia-Vidal et al. [23]	Spain	Retrospective cohort	2020	62	989	2.93 (1.97–4.18)
Dir et al. [24]	USA	Retrospective cohort	2020	57	350	1.71 (0.63–3.69)
Gupta et al. [26]	India	Retrospective cohort	2020	36	1073	2.50 (1.29–3.90)
Hazra et al. [27]	USA	Cross-sectional	2020	NA	459	0.0 (0.0–0.80)
Hirotsu et al. [28]	Japan	Cross-sectional	2020	NA	40	0.0 (0.0–8.81)
Hughes et al. [29]	UK	Retrospective case series	2020	69.5	836	3.23 (2.14–4.66)
Intra et al. [30]	Italy	Retrospective cohort	2020	NA	61	68.85 (55.71–80.10)
Karami et al. [31]	The Netherlands	Retrospective cohort	2020	70	925	0.86 (0.37–1.70)
Kim et al. [32]	USA	Cross-sectional	2020	46.9	116	0.0 (0.0–3.13)
Kimmig et al. [33]	USA	Retrospective cohort	2020	46.9	111	37.84 (28.80–47.54)
Li et al. [34]	China	Retrospective cohort	2020	66.2	1495	20.60 (18.58–22.74)
Li et al. [35]	China	Case series	2020	57	32	31.25 (16.12–50.1)
Liu et al. [36]	China	Retrospective case series	2020	46.5	20	20.0 (5.73–43.66)
Lv et al. [37]	China	Retrospective cohort	2020	62	354	14.12 (10.67–18.19)
Ma et al. [38]	China	Case series	2020	45.5	250	9.60 (6.25–13.95)
Massey et al. [39]	USA	Retrospective case series	2020	62.3	790	55.44 (51.90–58.95)
Motta et al. [40]	Multiplace[a]	Cohort	2020	NA	69	7.25 (2.39–16.11)
Neto et al. [25]	USA	Retrospective cohort	2020	66	242	19.10 (14.27–24.53)
Verroken et al. [52]	The Netherlands	Cohort	2020	NA	32	18.75 (7.21–36.44)
Nori et al. [41]	USA	Retrospective cohort	2020	62	152	44.80 (36.40–52.35)
Pandey et al. [51]	India	Cross-sectional	2020	NA	120	13.33 (7.82–20.75)
Porretta et al. [42]	Italy	Cohort	2020	67.4	331	9.67 (6.71–13.37)
Ripa et al. [43]	Italy	Cohort	2020	64	731	7.25 (5.48–9.38)
Rothe et al. [44]	Germany	Retrospective cohort	2020	63.5	140	76.43 (68.52–83.19)
Sepulveda et al. [46]	USA	Retrospective cohort	2020	NA	28,011	3.80 (3.58–4.30)
Sharifipour et al. [47]	Iran	Case series	2020	67.1	19	100.0 (82.35–100.0)
Sharov et al. [48]	Russia	Retrospective case series	2020	NA	147	75.51 (67.74–82.22)
Sy et al. [49]	Philippine	Cohort	2020	44.21	12,513	0.90 (0.74–1.80)
Tadolini M et al. [50]	Multiplace	Cohort	2020	48	49	85.71 (72.76–94.6)
Wu et al. [53]	China	Retrospective case series	2020	6	74	47.30 (35.57–59.25)
Youngs et al. [54]	UK	Cohort	2020	59	36	30.56 (16.35–48.11)
Yu et al. [55]	Sweden	Cohort	2020	NA	2240	10.90 (8.87–11.41)
Zha et al. [56]	China	Retrospective cohort	2020	57	874	2.52 (1.58–3.79)
Zhang et al. [57]	China	Retrospective cohort	2020	64.76	38	57.89 (40.82–73.69)

Abbreviation: NA, not available.
[a]Belgium, Brazil, France, Italy, Russia, Singapore, Spain, and Switzerland.

Bacterial coinfection among patients infected with influenza virus has been reported up to 30% [1].

One of the important aspects of determining the incidence and prevalence of bacterial coinfection is related to antibiotic prescription for patients with COVID-19 [25]. Although the use of antibiotics in coronavirus patients is rapidly growing, the effectiveness of them is under questioning. A number of studies have questioned the amount of prescribing antibiotics for the patients and have opinioned that this will cause us another great challenge, which is antibiotic resistance, but on the other hand, utilization of antibiotic in the pandemic situation is inevitable for different reasons, such as the difficulties of excluding bacterial coinfection and the possibility of secondary infection in patients [62].

More than 70% of patients with COVID-19 received some kind of antibiotics with a focus on broad-spectrum agents, such as fluoroquinolones and third-generation cephalosporins [59]. Bacterial coinfection was also reported in previous pandemics. During the 2009 influenza (H1N1) pandemic, patients in intensive care units showed up to 30% of bacterial coinfection. The most commonly identified pathogens were *S. aureus* and *S. pneumoniae* [1,63].

In contrast, in the recent COVID-19 pandemic, it becomes more and more clear that gram-negative and atypical bacteria are the most isolated bacteria from SARS-CoV-2 patients. A meta-analysis study showed that the most common organisms reported by the studies were *Mycoplasma* species, *Haemophilus influenzae*, and *Pseudomonas aeruginosa* [59].

Gram-negative microorganisms were also reported as the most frequent cause of lower respiratory tract infection. *Pseudomonas aeruginosa* was the most common isolated bacteria among patients with ventilator-associated pneumonia (38%) and tracheobronchitis (33%) [64]. Another systematic review and meta-analysis showed that the commonest bacteria were Mycoplasma pneumonia, Pseudomonas aeruginosa, and Haemophilus influenzae [60].

But there are controversial data about SARS-CoV-2 coinfection with these bacteria. Langford *et al.* showed that these

FIG. 2. Forest plot for the prevalence of bacterial coinfections in patients with COVID-19 based on a random effects model. Each study identifies by the first author (year) and country. Each line segment's midpoint shows the prevalence estimate, length of line segment indicates 95% CI in each study, and diamond mark illustrates the pooled estimate.

bacterial pathogens are not common amongst people with COVID-19, yet another meta-analysis study reported the rate of *S. aureus*/COVID-19 coinfection was 25.6%, and the proportion of COVID-19/MRSA *S. aureus* was 53.9%, which has been collected from five different studies [59,65].

Johns' Hopkins scientists in a multicentre study found only 1.2% of the patients had bacterial coinfection, which is less frequent than in other studies. The researchers suggested that their varied data may be related to inclusion and exclusion criteria used by them [66]. They also mentioned their sampling time could be an effective factor compared with other studies. Their study was conducted in spring, whereas other studies were implemented during winter in Europe and China. They also indicated variation in vaccination background of sample

population against pneumococcal infection, and this may also affect the coinfection prevalence [67].

Although it is not the main focus of our study, it is worth mentioning the coinfection of other microorganisms, such as viruses and fungi with SARS-CoV-2. The rate of fungal coinfection with SARS-CoV-2 has been reported diversely.

A systematic review and meta-analysis conducted by Jackson S. Musuuza found the prevalence of fungal coinfections, 4% and fungal superinfections, 8% among patients with COVID-19 [68]. In contrast, another study reported that the overall pooled proportion of patients with coinfection was only 0.12 [69]. It should be mentioned that *Aspergillus* and *Candida* species were the most frequently reported among patients with COVID-19. Viral coinfections and viral superinfections were reported 10%

FIG. 3. Pooled prevalence with 95% CI and heterogeneity indices of bacterial coinfections in patients with COVID-19 based on the type of the bacteria, different regional places (AMRO: Regional Office of Americas; EURO: Regional Office for Europe; SEARO: Regional Office for South-East Asia; EMRO: Regional Office for the Eastern Mediterranean; WPRO; Regional Office for the Western Pacific) and the type of the study. The diamond mark illustrates the pooled prevalence, and the length of the diamond indicates the 95% CI. *N* is the number of the study in the analysis. The prevalence for EMRO (*N* = 1) was 100 % (95% CI: 82.35−100.00).

and 4%, respectively, and the most frequently identified viruses among patients were influenza type A (22.3%), influenza type B (3.8%), and respiratory syncytial virus (3.8%) [68].

TABLE 2. The univariate meta-regression analysis on the hertogenisity of the determinants in included studies for bacterial coinfections in patients with COVID-19.

Variables	Coefficient	95% CI	p value
Age (year)	−0.205	−1.103 to 0.692	0.643
WHO region (score)	−5.304	−14.739 to 4.131	0.262
Sample size (number)	−0.001	−0.003 to 0.001	0.215
Type of the study (score)	20.274	5.768 to 34.781	0.007

Coding of WHO region: 1 = EMRO; 2 = EURO; 3 = AMRO; 4 = WPRO; 5 = SEARO; Coding of type of the study: 1 = cross-sectional; 2 = cohort; 3 = case series.

Our results showed the 5.2% pooled prevalence for respiratory bacterial coinfection and gastrointestinal subtype had 4.79% amongst patients with COVID-19, which are in consistent with previous research reported the ranged of bacterial coinfection between 3.1% and 7%. We also found that case series studies reported the highest level of coinfection compared with cross-sectional studies, which showed the lowest rate. From geographical viewpoint, we acquired some interesting results. Our analysis exhibit that the WPRO has 20.15% and AMRO had 13.97% of coinfection, which shows a great difference between these regions. Our meta-analysis showed the pooled estimate for the prevalence of bacterial coinfections was 20.97%. Our results clearly indicate the high

FIG. 4. Association among prevalence of age (A) and sample size (B) with the prevalence of bacterial coinfections by means of meta-regression. The size of circles indicates the precision of each study. There is no significant association with respect to the prevalence of bacterial coinfections with age and sample size.

prevalence of bacterial pathogens amongst patients with COVID-19. Therefore, we came to the conclusion that pre-scribing antibiotics for patients with COVID-19 based on the high percentage of bacterial coinfection is inevitable.

The currents evidence is against the massive use of antibi-otics to treat patients with COVID-19 in both hospitalized and critically ill state, but it has been mentioned in this manuscript that the circumstances can be different from one to another patient situation, and it also should be noted that the data are still progressing almost every day, so it would be wise for cli-nicians to use antibiotics with cautions and always update themselves with the latest research.

Escalation in patient's body temperature, longer fever duration, anhelation, gastrointestinal-related symptoms, intensive care unit attending, ventilation treatment, glucocor-ticoid therapy, severity in disease situation, and prolongation in hospitalization time were reported as different sequences of clinical outcome linked to bacterial coinfection [67]. The data have reported the elderly patients with high level of inflam-matory factors and worse lymphopenia and cardiovascular comorbidities have a higher chance of being infected with bacterial infection. In addition, these patients had worsened illness situations and showed multiple set of system failure [29,67].

The laboratory results of patients with COVID-19 have several clinical risk factors related to coinfection. A case–control study reported that C-reactive protein and median neutrophil to lymphocyte ratio were significantly higher in case compared to controls. However, there was not any statistical significance in procalcitonin levels in patients with COVID-19 with bacterial infection compared with people without bacterial infection [69]. Shengyang *et al.* found that patients with COVID-

19 with bacterial coinfection had substantially increase in their procalcitonin. This article also confirms the increase in C-reactive protein in the patients [67].

Similar to other studies, our research had some limitations. (1) we would like to perform the gender-specific estimation, but it was not possible because of insufficient data in the pri-mary studies; (2) we estimated the pooled prevalence based on WHO regional office and tendency to examine the spatial analysis in different geographical regions based on available methods [70–72], but because of the infrequent studies num-ber, this estimation will not be robust. Also, in the SEARO subgroup, we have only two studies, and this may cause unrobust estimates. Doing a comprehensive search and esti-mate the pooled prevalence based on different bacteria sub-types was the present study's strengths.

Conclusion

Because of the proven track of bacterial coinfection in increasing morbidity and mortality rate in previous viral out-breaks and pandemics, proving information about the incidence and prevalence rate of them are crucial for health administra-tors and clinicians, but the contrary data prove that various factors affect the final output of the studies, and setting clinical guidelines or prescribing medication based on the results of different research should be done carefully and considering all the factor, which yield effect on the final results. Considering the multiple complications and adverse effects of extensive use of antibiotics in patients with COVID-19, it seems there is no other option except applying them, but it needs to be done carefully.

Authors' contributions

S.S. contributed to study design, creation of models, and management activities to annotate (produce metadata), specifically writing the initial draft (including substantive translation).

S.F. contributed to data collection and writing the article, developed the theory, and performed the computations, specifically writing the initial draft (including substantive translation).

M.Z. contributed to data collection, writing the article, and conducting a research and investigation process.

R.S. contributed to data collection, writing the article, and conducting a research and investigation process.

A.J. contributed to data collection, writing the article, and conducting a research and investigation process.

S.A.R. contributed to data collection and writing the article.

I.P. contributed to study design and writing the article.

F.A. contributed to data collection and writing the article.

P.M. contributed to management and coordination responsibility for the research activity planning and execution, study design, data analysis, development or design of methodology, and creation of models.

R.P. contributed to design and perform the idea, data analysis, development or design of methodology, and creation of models.

Funding sources

Conflict of interest

None.

Appendix A. Supplementary data

Supplementary data related to this article can be found at doi:10.1016/j.nmni.2021.100910.

References

[1] Rice TW, Rubinson L, Uyeki TM, Vaughn FL, John BB, Miller III RR, et al. Critical illness from 2009 pandemic influenza A (H1N1) virus and bacterial co-infection in the United States. Crit Care Med 2012;40(5): 1487.

[2] Taubenberger JK, Morens DM. The 1918 influenza pandemic and its legacy. Cold Spring Harbor Perspect Med 2020;10(10):a038695.

[3] Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, et al. Critically ill patients with 2009 influenza A (H1N1) infection in Canada. Jama 2009;302(17):1872–9.

[4] Joseph C, Togawa Y, Shindo N. Bacterial and viral infections associated with influenza. Influenza Other Respirat Viruse 2013;7:105–13.

[5] Beadling C, Slifka MK. How do viral infections predispose patients to bacterial infections? Curr Opin Infect Dis 2004;17(3):185–91.

[6] Organization WH. Clinical management of COVID-19: interim guidance, 27 May 2020. World Health Organization; 2020.

[7] Bengoechea JA, Bamford CG. SARS-CoV-2, bacterial co-infections, and AMR: the deadly trio in COVID-19? EMBO Mol Med 2020;12(7): e12560.

[8] Hsu J. How covid-19 is accelerating the threat of antimicrobial resistance. BMJ 2020:369.

[9] Chibabhai V, Duse A, Perovic O, Richards G. Collateral damage of the COVID-19 pandemic: exacerbation of antimicrobial resistance and disruptions to antimicrobial stewardship programmes? SAMJ: South African Med J 2020;110(7):1–2.

[10] Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6(7):e1000097.

[11] Wells GA, Shea B, O'Connell Da, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. Oxford. 2000.

[12] Hashemi H, Pakzad R, Yekta A, Aghamirsalim M, Pakbin M, Ramin S, et al. Global and regional prevalence of age-related cataract: a comprehensive systematic review and meta-analysis. Eye 2020;34(8): 1357–70.

[13] Hallajzadeh J, Khoramdad M, Izadi N, Karamzad N, Almasi-Hashiani A, Ayubi E, et al. Metabolic syndrome and its components in premenopausal and postmenopausal women: a comprehensive systematic review and meta-analysis on observational studies. Menopause 2018;25(10):1155–64.

[14] Hashemi H, Pakzad R, Heydarian S, Yekta A, Aghamirsalim M, Shokrollahzadeh F, et al. Global and regional prevalence of strabismus: a comprehensive systematic review and meta-analysis. Strabismus 2019;27(2):54–65.

[15] Hashemi H, Pakzad R, Yekta A, Bostamzad P, Aghamirsalim M, Sardari S, et al. Global and regional estimates of prevalence of amblyopia: a systematic review and meta-analysis. Strabismus 2018;26(4):168–83.

[16] Soltani S, Tabizadeh A, Zakeri A, Zakeri AM, Latifi T, Shabani M, et al. COVID-19 associated central nervous system manifestations, mental and neurological symptoms: a systematic review and meta-analysis. Rev Neurosci 2021:1 (ahead-of-print).

[17] Blasco ML, Buesa J, Colomina J, Forner MJ, Galindo MJ, Navarro J, et al. Co-detection of respiratory pathogens in patients hospitalized with Coronavirus viral disease-2019 pneumonia. J Med Virol 2020;92(10): 1799–801.

[18] Chauhdary WA, Chong PL, Mani BI, Asli R, Momin RN, Abdullah MS, et al. Primary respiratory bacterial coinfections in patients with COVID-19. Am J Trop Med Hygiene 2020;103(2):917.

[19] Cheng LS-k, Chau SK-y, Tso EY-k, Tsang SW-c, Li IY-f, Wong BK-c, et al. Bacterial co-infections and antibiotic prescribing practice in adults with COVID-19: experience from a single hospital cluster. Therapeut Adv Infect Dis 2020;7. 2049936120978095.

[20] Contou D, Claudinon A, Pajot O, Micaëlo M, Longuet Flandre P, Dubert M, et al. Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. Ann Inten Care 2020;10(1):119.

[21] D'Onofrio V, Van Steenkiste E, Meersman A, Waumans L, Cartuyvels R, Van Halem K, et al. Differentiating influenza from

COVID-19 in patients presenting with suspected sepsis. Euro J Clin Microbiol Infect Dise 2020:1–9.

[22] Fu Y, Yang Q, Xu M, Kong H, Chen H, Fu Y, et al., editors. Secondary bacterial infections in critical ill patients of COVID-19. Open forum infectious diseases; 2020.

[23] Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al. Incidence of co-infections and super-infections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect 2021;27(1):83–8.

[24] Gayam V, Konala VM, Naramala S, Garlapati PR, Merghani MA, Regmi N, et al. Presenting characteristics, comorbidities, and outcomes of patients coinfected with COVID-19 and Mycoplasma pneumoniae in the USA. J Med Virol 2020;92(10):2181–7.

[25] Goncalves Mendes Neto A, Lo KB, Wattoo A, Salacup G, Pelayo J, DeJoy III R, et al. Bacterial infections and patterns of antibiotic use in patients with COVID-19. J Med Virol 2021;93(3):1489–95.

[26] Gupta N, Ish P, Gupta A, Malhotra N, Caminero JA, Singla R, et al. A profile of a retrospective cohort of 22 patients with COVID-19 and active/treated tuberculosis. Euro Respirat J 2020;56(5).

[27] Hazra A, Collison M, Pisano J, Kumar M, Oehler C, Ridgway JP. Coinfections with SARS-CoV-2 and other respiratory pathogens. Infect Contr Hospit Epidemiol 2020;41(10):1228–9.

[28] Hirotsu Y, Maejima M, Shibusawa M, Amemiya K, Nagakubo Y, Hosaka K, et al. Analysis of Covid-19 and non-Covid-19 viruses, including influenza viruses, to determine the influence of intensive preventive measures in Japan. J Clin Virol 2020;129:104543.

[29] Hughes S, Troise O, Donaldson H, Mughal N, Moore LS. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect 2020;26(10):1395–9.

[30] Intra J, Sarto C, Beck E, Tiberti N, Leoni V, Brambilla P. Bacterial and fungal colonization of the respiratory tract in COVID-19 patients should not be neglected. Am J Infect Contr 2020;48(9):1130–1.

[31] Karami Z, Knoop BT, Dofferhoff AS, Blaauw MJ, Janssen NA, van Apeldoorn M, et al. Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands. Infect Dise 2021;53(2):102–10.

[32] Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of Co-infection between SARS-CoV-2 and other respiratory pathogens. JAMA 2020;323(20):2085–6.

[33] Kimmig LM, Wu D, Gold M, Pettit NN, Pitrak D, Mueller J, et al. Il-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections. Fron Med 2020;7.

[34] Li J, Wang J, Yang Y, Cai P, Cao J, Cai X, et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis. Antimicrobial Resist Infect Contr 2020;9(1):1–7.

[35] Li Z, Chen Z-m, Chen L-D, Zhan Y-Q, Li S-Q, Cheng J, et al. Coinfection with SARS-CoV-2 and other respiratory pathogens in patients with COVID-19 in Guangzhou, China. J Med Virol 2020;92(11):2381–3.

[36] Liu J, Zeng W, Cao Y, Cui Y, Li Y, Yao S, et al. Effect of a previous history of antiretroviral treatment on the clinical picture of patients with co-infection of SARS-CoV-2 and HIV: a preliminary study. Int J Infect Dise 2020;100:141–8.

[37] Lv Z, Cheng S, Le J, Huang J, Feng L, Zhang B, et al. Clinical characteristics and co-infections of 354 hospitalized patients with COVID-19 in Wuhan, China: a retrospective cohort study. Microbes Infect 2020;22(4):195–9.

[38] Ma L, Wang W, Le Grange JM, Wang X, Du S, Li C, et al. Coinfection of SARS-CoV-2 and other respiratory pathogens. Infect Drug Resist 2020;13:3045.

[39] Massey BW, Jayathilake K, Meltzer HY. Respiratory microbial Co-infection with SARS-CoV-2. Front Microbiol 2020;11:2079.

[40] Motta I, Centis R, D'Ambrosio L, García-García JM, Goletti D, Gualano G, et al. Tuberculosis, COVID-19 and migrants: preliminary analysis of deaths occurring in 69 patients from two cohorts. Pulmonology 2020;26(4):233–40.

[41] Nori P, Cowman K, Chen V, Bartash R, Szymczak W, Madaline T, et al. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. Infect Cont Hosp Epidemiol 2021;42(1):84–8.

[42] Porretta AD, Baggiani A, Arzilli G, Casigliani V, Mariotti T, Mariottini F, et al. Increased risk of acquisition of New Delhi metallo-beta-lactamase-producing carbapenem-resistant Enterobacterales (NDM-CRE) among a cohort of COVID-19 patients in a teaching hospital in Tuscany, Italy. Pathogens 2020;9(8):635.

[43] Ripa M, Galli L, Poli A, Oltolini C, Spagnuolo V, Mastrangelo A, et al. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. Clin Microbiol Infect 2020.

[44] Rothe K, Feihl S, Schneider J, Wallnöfer F, Wurst M, Lukas M, et al. Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship. Euro J Clin Microbiol Infect Dise 2020:1–11.

[45] Sarınoğlu RC, Sili U, Eryuksel E, Yildizeli SO, Cimsit C, Yagci AK. Tuberculosis and COVID-19: an overlapping situation during pandemic. J Infect Develop Countr 2020;14(7):721–5.

[46] Sepulveda J, Westblade LF, Whittier S, Satlin MJ, Greendyke WG, Aaron JG, et al. Bacteremia and blood culture utilization during COVID-19 surge in New York City. J Clin Microbiol 2020;58(8).

[47] Sharifipour E, Shams S, Esmkhani M, Khodadadi J, Fotouhi-Ardakani R, Koohpaei A, et al. Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU. BMC Infect Dise 2020;20(1):1–7.

[48] Sharov KS. SARS-CoV-2-related pneumonia cases in pneumonia picture in Russia in March-May 2020: secondary bacterial pneumonia and viral co-infections. J Glob Health 2020;10(2). 020504.

[49] Sy KTL, Haw NJL, Uy J. Previous and active tuberculosis increases risk of death and prolongs recovery in patients with COVID-19. Infect Dise 2020;52(12):902–7.

[50] Tadolini M, Codecasa LR, García-García J-M, Blanc F-X, Borisov S, Alffenaar J-W, et al. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. Euro Respirat J 2020;56(1).

[51] Tiwari Pandey A, Pandey I, Zamboni P, Gemmati D, Kanase A, Singh AV, et al. Traditional herbal remedies with a multifunctional therapeutic approach as an implication in COVID-19 associated Co-infections. Coatings 2020;10(8):761.

[52] Verroken A, Scohy A, Gérard L, Wittebole X, Collienne C, Laterre P-F. Co-infections in COVID-19 critically ill and antibiotic management: a prospective cohort analysis. Crit Care 2020;24(1):1–3.

[53] Wu Q, Xing Y, Shi L, Li W, Gao Y, Pan S, et al. Coinfection and other clinical characteristics of COVID-19 in children. Pediatrics 2020;146(1).

[54] Youngs J, Wyncoll D, Hopkins P, Arnold A, Ball J, Bicanic T. Improving antibiotic stewardship in COVID-19: bacterial co-infection is less common than with influenza. J Infect 2020.

[55] Yu D, Ininbergs K, Hedman K, Giske CG, Strålin K, Özenci V. Low prevalence of bloodstream infection and high blood culture contamination rates in patients with COVID-19. PloS One 2020;15(11):e0242533.

[56] Zha L, Shen J, Tefsen B, Wang Y, Lu W, Xu Q. Clinical features and outcomes of adult COVID-19 patients co-infected with Mycoplasma pneumoniae. J Infect 2020.

[57] Zhang H, Zhang Y, Wu J, Li Y, Zhou X, Li X, et al. Risks and features of secondary infections in severe and critical ill COVID-19 patients. Emerging Microbes & Infections 2020;9(1):1958–64.

[58] Zhu X, Ge Y, Wu T, Zhao K, Chen Y, Wu B, et al. Co-infection with respiratory pathogens among COVID-2019 cases. Virus Res 2020;285:198005.

[59] Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in

patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect 2020.

[60] Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect 2020;81(2): 266−75.

[61] Kash JC, Walters K-A, Davis AS, Sandouk A, Schwartzman LM, Jagger BW, et al. Lethal synergism of 2009 pandemic H1N1 influenza virus and Streptococcus pneumoniae coinfection is associated with loss of murine lung repair responses. MBio 2011;2(5).

[62] Goel N, Ahmad R, Fatima H, Khare SK. New threatening of SARS-CoV-2 co-infection and strategies to fight the current pandemic. Med Drug Disc 2021:100089.

[63] MacIntyre CR, Chughtai AA, Barnes M, Ridda I, Seale H, Toms R, et al. The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a (H1N1) pdm09. BMC Infect Dise 2018;18(1):1−20.

[64] Bardi T, Pintado V, Gomez-Rojo M, Escudero-Sanchez R, Lopez AA, Diez-Remesal Y, et al. Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome. Euro J Clin Microbiol Infect Dise 2021;40(3):495−502.

[65] Adeiza SS, Shuaibu AB, Shuaibu GM. Random effects meta-analysis of COVID-19/S. aureus partnership in co-infection. GMS Hygiene Infect Cont 2020;15.

[66] Prevalence of Co-infection at the time of hospital admission in COVID-19 patients, A multicenter study. In: Karaba SM, Jones G, Helsel T, Smith LL, Avery R, Dzintars K, et al., editors. Open forum infectious diseases. Oxford University Press US; 2021.

[67] He S, Liu W, Jiang M, Huang P, Xiang Z, Deng D, et al. Clinical characteristics of COVID-19 patients with clinically diagnosed bacterial co-infection: a multi-center study. Plos One 2021;16(4): e0249668.

[68] Musuuza JS, Watson L, Parmasad V, Putman-Buehler N, Christensen L, Safdar N. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis. PloS One 2021;16(5):e0251170.

[69] Nasir N, ur Rehman F, Omair SF. Risk factors for bacterial infections in patients with moderate to severe COVID-19: a case control study. medRxiv 2021. 2021.01. 09.21249498.

[70] Holakouie-Naieni K, Mostafavi E, Boloorani AD, Mohebali M, Pakzad R. Spatial modeling of cutaneous leishmaniasis in Iran from 1983 to 2013. Acta Trop 2017;166:67−73.

[71] Pakzad R, Dabbagh-Moghaddam A, Mohebali M, Safiri S, Barati M. Spatio-temporal analysis of cutaneous leishmaniasis using geographic information system among Iranian Army Units and its comparison with the general population of Iran during 2005−2014. J Parasit Dise 2017;41(4):1114−22.

[72] Pakzad R, Pakzad I, Safiri S, Shirzadi MR, Mohammadpour M, Behroozi A, et al. Spatiotemporal analysis of brucellosis incidence in Iran from 2011 to 2014 using GIS. Int J Infect Dise 2018;67: 129−36.